Bright Minds Biosciences Inc.

DRUG

Healthcare Biotechnology

EPS
+67.9%
Free cash flow
−124.6%
Total debt
−84.7%

Quarter to June 2026, against a year earlier

23.00 2.30 +11.11%
Market cap
$226.9M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
6.0×
Dividend safety
n/a
Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Dec '20 Sep '20 Sep '19 Sep '17
Current Ratio
36.10 11.33 24.25 8.11 31.38 31.38 31.38 2.18 —
Net Debt/EBITDA
5.98 2.07 0.92 0.77 2.25 7.99 7.99 1.02 —
Debt/Equity
0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 —
ROE
(27.88%) (45.96%) (83.16%) (99.25%) (169.76%) 93.93% 9.97% (18.59%) —
ROA
(26.97%) (42.96%) (75.07%) (92.53%) (43.17%) (43.17%) (4.48%) (95.98%) —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(14.92%) (51.33%) (112.87%) (142.85%) (44.59%) (44.59%) (2.33%) (181.76%) —
Average Days of Receivables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
Free Cash Flow per Share
(0.90) (0.32) (1.40) (4.31) (3.23) — (0.30) (0.02) —
Book value per Share
8.53 0.94 1.32 3.34 8.56 0.00 21.26 0.08 —
Free Cash Flow
(6.21) (1.36) (5.21) (10.64) (5.79) — (0.22) (0.03) —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026